Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Exagen (XGN) Research & Development (2018 - 2026)

Exagen filings provide 9 years of Research & Development readings, the most recent being $1.6 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 20.95% to $1.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $6.5 million, a 16.48% increase, with the full-year FY2025 number at $6.3 million, up 16.35% from a year prior.
  • Research & Development hit $1.6 million in Q1 2026 for Exagen, down from $1.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $2.7 million in Q4 2022 to a low of $1.1 million in Q1 2024.
  • Median Research & Development over the past 5 years was $1.5 million (2025), compared with a mean of $1.6 million.
  • Biggest five-year swings in Research & Development: crashed 60.16% in 2023 and later surged 53.9% in 2024.
  • Exagen's Research & Development stood at $2.7 million in 2022, then tumbled by 60.16% to $1.1 million in 2023, then surged by 53.9% to $1.7 million in 2024, then rose by 6.1% to $1.8 million in 2025, then fell by 11.61% to $1.6 million in 2026.
  • The last three reported values for Research & Development were $1.6 million (Q1 2026), $1.8 million (Q4 2025), and $1.7 million (Q3 2025) per Business Quant data.